Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for patients worldwide. Its research and product pipeline spans eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and hematologic conditions. The company’s marketed medicines include EYLEA injections for several retinal and eye disorders, Dupixent for atopic dermatitis and asthma, Libtayo for certain cutaneous squamous cell carcinoma indications, Praluent for heterozygous familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. Regeneron also has collaboration and licensing arrangements with Bayer, Alnylam Pharmaceuticals, Intellia Therapeutics, Hansoh Pharmaceuticals Group, and Tessera Therapeutics. Incorporated in 1988, Regeneron is based in Tarrytown, New York, and its common stock trades on NASDAQ under the symbol REGN.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-REGN
|
$1,118
|
52.1% Upside
|
Bargain
|
$855.12
|
16.3% Upside
|
Fair
|
Great
|
0.5%
|
October 30, 2026
|
17.0x
|
2.3x
|
4.7x
|
72.542 B
|
47.993 B
|
3.6%
|
96.0%
|
6.8
|
8.7%
|
86.9%
|
